Cash Is Not a Cure: The Insurance Gaps Behind Falling GLP-1 Prices

“Lower is better, but ‘lower’ doesn’t automatically mean accessible.”

Why it’s easier and cheaper for you to buy GLP-1s

On March 12, 2026, The Washington Post published an article titled “Why it’s easier and cheaper for you to buy GLP-1s,” describing how the prices of weight-loss drugs are falling despite their novelty. While this article highlights how gaps in insurance coverage contribute to GLP-1 inaccessibility, it frames the cash market created from these gaps as a potential solution rather than a symptom of current pricing dynamics.

The Biotech Social Contract is an unspoken agreement between the industry and society, in which biotech companies take massive risks and spend billions to develop new medicines. In exchange, these companies receive a limited window (approximately 10–15 years) to sell those drugs at a profit, recoup their investment, and fund the next generation of therapies. Once that window closes, the drug falls off the patent cliff and becomes a low-cost generic forever.

While Zepbound’s $1,086 list price in 2026 often draws criticism, it represents the reward phase in which companies like Eli Lilly and Novo Nordisk recoup their massive R&D investments. Once patent windows expire, these same life-saving molecules will cost only a fraction of their initial prices as they transition to the generic market.

Unlike hospital stays, nursing homes, or surgeries, which become more expensive over time, drugs eventually become a commodity. Thus, every person who uses a GLP-1 today to avoid a future heart attack, stroke, or kidney failure is ultimately saving the system hundreds of thousands of dollars in long-term costs.

KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use

The Post states, “GLP-1 drugs are generally covered for diabetes, but insurance companies and employers have been more reluctant to do the same for weight loss. This is largely because GLP-1’s are so popular and require long-term use often enough that total spending threatens to spiral out of control,” echoing the insurance industry’s fear of high GLP-1 spending costs. Yet, this is the same rhetoric used for many blockbuster drugs. The use of statins by United States adults (40 years or older) rose by 79.8% from 2002 to 2013, while the total expenditures on statins decreased from $17.2 billion to $16.9 billion. Generic drug competition drove down the cost of statins despite increased usage. As safe generics become available for GLP-1’s, a similar trend may occur.

Total spending only truly spirals if drug costs are considered in a vacuum. Instead, the attention to drug costs should be focused on the financial burden on patients due to the reluctance of insurance companies and employers to cover GLP-1 drugs for weight loss.

Under current law, states may choose whether to cover weight-loss drugs under Medicaid. This is unusual, as state Medicaid programs are obligated to cover nearly all Food and Drug Administration (FDA) approved drugs. Due to this exception, only thirteen state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service as of January 2026. According to a KFF poll, 56% of users said GLP-1’s were difficult to afford, with one in four saying they were “very difficult” to afford. Additionally, 27% of GLP-1 users reported having insurance but still paid the whole cost. Unless Medicaid covers GLP-1’s, these drugs are still inaccessible to Medicaid enrollees due to the high out-of-pocket cost, even at lower prices.

KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use

The Post mentions the White House’s new TrumpRx referral site, a government-run cash-pay portal. While lowering prices seems like a win for individual consumers, the government’s role is to ensure coverage, not just to act as a discount broker. When the government starts a referral site for cash-paying patients, it is essentially admitting that the insurance system has failed. Furthermore, manufacturers are creating robust direct-to-consumer cash channels (Novo Nordisk’s $199–$349/month tiers, Eli Lilly’s $299–$449/month tiers) that operate as secondary sales channels outside of insurance. Yet this reduces pressure on insurers to cover these drugs, and patients are still paying out of pocket. The Post introduces Ashley Elizabeth Harden, a Louisiana resident who purchased a cheaper, imitation version of GLP-1 drugs for $177 a month without going through insurance. Despite its lower list price compared to branded drugs, this imitation drug is still a strain on her family. Harden herself states,

“Lower is better, but ‘lower’ doesn’t automatically mean accessible.”

The Washington Post article highlights the oddity of current GLP-1 pricing dynamics and the insurance gaps that led us to this point. It describes the financial burden of the current drug pricing system on individual patients. However, it misleadingly suggests that the creation of cash markets indicates increased accessibility. Instead of treating cash markets as a substitute for real coverage reform, expanding Medicaid and Medicare coverage of GLP-1s would align the system with what the Biotech Social Contract promises: that breakthrough medicines reach every patient who needs them, not just those who can afford to pay out of pocket.

Recently, the Centers for Medicare & Medicaid Services (CMS) has proposed temporary coverage expansions to GLP-1 medications for weight loss called the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model. Under this voluntary, five-year program, patients pay a lower price for GLP-1’s and pair the medication with intensive lifestyle interventions such as nutrition counseling. Notably, the $50 copayment toward these medications will not count toward a participant’s Part D deductible, or the $2,100 out-of-pocket maximum in 2026. While the program was expected to begin for participating Medicaid agencies in mid-2026, its Medicare component has faced delays due to concerns from private insurers regarding the high volume of potential claims and overall program costs. Despite these hurdles, the BALANCE Model sets a potentially promising new precedent for drug affordability, signaling a vital systemic shift toward bridging the gap between clinical innovation and true patient access.

This article was developed during my time with the No Patient Left Behind Fellowship, a program dedicated to fostering a more nuanced understanding of the biotechnology industry. I would like to thank Harrison Bergeron, Elena Solopova, and Peter Kolchinsky for their support and guidance.